Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Obesity Treatment Coverage topic
No spam. Unsubscribe anytime.
Senate committee advances bill to require insurers to cover obesity treatments, sparking fiscal debate
Summary
Senate Bill 48 — proposing coverage of FDA‑approved anti‑obesity medications, behavioral and surgical treatments — advanced from Health & Human Services after lengthy testimony for and against and an actuarial review showing sizable premium impacts over several years.
Senate Bill 48, which would require insurance coverage of comprehensive obesity treatment including medical nutrition therapy, anti‑obesity drugs and bariatric surgery, cleared the Senate Health and Human Services Committee on a 5–3 vote after a long, often contentious hearing.
Sponsor Senator Michaelson‑Genet framed the bill as a public‑health and cost‑saving intervention, citing Milliman actuarial work the sponsor presented that showed long‑term medical offset assumptions could deliver net savings over a 10‑year horizon. Multiple patient advocates, clinicians and nonprofit medical organizations — including the American Diabetes Association, the Obesity Medicine Association, Children’s Hospital Colorado and National Jewish Health — testified in favor, describing clinical evidence that modern GLP‑1 receptor agonists and other treatments can reduce diabetes, cardiovascular risk and other obesity‑related complications.
Opponents, including state insurance regulators and major stakeholders representing employer purchasers, pharmacy benefit managers and health plans, warned of near‑term premium impacts. The state insurance commissioner summarized an analysis showing an estimated first‑year premium impact to the commercial market in the tens of millions of dollars and multi‑year premium increases, even when modeling medical offsets. Representatives of employer coalitions and pharmacy benefit managers said the mandate could raise premiums for employers and employees and recommended federal or market‑level solutions instead.
Senator Michaelson‑Genet said updated price dynamics and recent reductions in list pricing for some branded drugs reduce estimated costs, and proponents urged the committee to consider coverage as an evidence‑based treatment pathway that can prevent more expensive downstream illnesses. Opponents urged caution because of near‑term budget constraints and uncertainty about utilization assumptions.
Committee action: SB 48 passed the committee on a 5–3 vote and was reported to the Committee on Appropriations. Several witnesses urged more work on targeting, prior‑authorization and program design to control costs.
Why it matters: The bill would expand the set of required insurance benefits to include anti‑obesity drugs and related services, which proponents say treat a chronic disease and prevent costly comorbidities; opponents cite estimated premium effects and uncertainty about long‑term offsets.
What’s next: SB 48 will go to the Appropriations Committee for fiscal review and possible modifications.
